BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Advaxis, Inc. Presents Lm-LLO Cancer Immunotherapy Data at the 2015 AACR Meeting 4/21/2015 4:42:03 PM
Advaxis, Inc. Included Among "25 Top Immunotherapy Companies" In Newly Launched Loncar Cancer Immunotherapy Index (LCINDX) 4/10/2015 8:42:44 AM
Advaxis, Inc. And Merck & Co. (MRK) Announce Initiation Of Enrollment In The Phase I/II Study Of ADXS-PSA In Combination With Anti-PD-1 Therapy, KEYTRUDA (Pembrolizumab), For The Treatment Of Advanced Prostate Cancer 4/8/2015 7:15:53 AM
Advaxis, Inc. And RTOG Foundation To Collaborate On Pivotal Phase 2/3 Clinical Trial Of ADXS-HPV In Anal Cancer 4/6/2015 6:53:35 AM
Advaxis, Inc. To Present At The Jefferies Immuno-Oncology Summit 3/30/2015 6:35:33 AM
Advaxis, Inc.'s Lm-LLO Immunotherapy Platform To Be Featured In Three Poster Presentations At The 2015 American Association for Cancer Research Annual Meeting 3/19/2015 7:43:34 AM
Advaxis, Inc. Announces First Patient Treated In Phase 1/2 Dose-Escalation Study Of ADXS-HPV For Recurrent Cervical Cancer 3/19/2015 7:18:48 AM
Advaxis, Inc. Presents Preliminary Data From A Phase I/II Trial Of ADXS-HPV In HPV-Associated Anal Cancer In Combination With Chemoradiation Showing Complete Response And No Recurrences To Date In All Treated Patientsa 3/16/2015 7:15:21 AM
Gynecologic Oncology Group Commences Enrollment In Stage 2 Of GOG-0265 Clinical Trial 3/11/2015 7:29:15 AM
Advaxis, Inc. To Present At The 27th Annual ROTH Conference 3/5/2015 7:55:59 AM
12345678910...